ProfileGDS5678 / 1423448_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 95% 95% 94% 94% 94% 94% 95% 95% 95% 95% 95% 95% 95% 95% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.4004495
GSM967853U87-EV human glioblastoma xenograft - Control 28.5931995
GSM967854U87-EV human glioblastoma xenograft - Control 38.3231994
GSM967855U87-EV human glioblastoma xenograft - Control 48.4434894
GSM967856U87-EV human glioblastoma xenograft - Control 58.1743994
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.0212994
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.3745895
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.3524195
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.3743295
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.4111395
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.4992795
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.3990995
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.4845195
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.357795